Oncology Billing Services: Why Cancer Care Practices Lose More Revenue Than Any Other Specialty

By Medtransic Editorial Team | March 8, 2026 | 9 min read | Updated: March 8, 2026

Quick Summary: Oncology practices handle the most expensive drug regimens in medicine, the most complex prior authorization requirements, and some of the highest denial rates of any specialty. If your billing company is not an oncology specialist, you are losing significant revenue every single month.

Oncology practices carry more financial risk per patient than almost any other specialty in medicine. The drug costs are enormous, the treatment regimens are complex, the prior authorization burden is relentless, and the margin between a correctly billed claim and a denied one is measured in thousands of dollars per patient per cycle. In that environment, a billing company that does not specialize in oncology is not just underperforming — it is actively costing your practice money on every treatment day.

Most oncology practices that come to Medtransic have been losing revenue for years without fully understanding why. The drug claims go out, some get paid, some get denied, a portion get written off, and the cycle repeats. What they discover during a Medtransic billing audit is that the write-offs were not inevitable — they were the predictable result of a billing company that was not equipped to handle the complexity of cancer care reimbursement.

• 15–25% Revenue Recovered - Average improvement after switching to specialist billing
• $100K+ Avg. Audit Finding - Recoverable revenue found in 90-day oncology billing reviews
• 32% Industry Denial Rate - Average oncology denial rate without specialist billing
• 97% Clean Claim Rate - Medtransic oncology clients after onboarding

The Revenue Problem Oncology Practices Face

No other specialty combines high drug costs, high claim values, high denial rates, and complex prior authorization requirements the way oncology does. A single chemotherapy infusion visit can generate a claim worth $10,000 to $50,000 or more. When that claim is denied — for a prior authorization gap, a drug HCPCS code error, a medical necessity documentation issue, or a dozen other reasons payers use — the financial impact on your practice is immediate and significant.

The practices most at risk are those where drug administration is a major revenue driver. Buy-and-bill chemotherapy, biologic therapies, immunotherapy agents — these represent the largest revenue line items in an oncology practice and the highest-risk claims from a billing standpoint. A billing company that does not understand oncology-specific drug billing, payer contract terms for chemotherapy, and the prior authorization workflows for each drug class will lose money on your most valuable claims consistently.

Why Oncology Billing Is Unlike Any Other Specialty

Oncology billing requires expertise that simply does not transfer from general medical billing experience. The drug reimbursement model, the prior authorization landscape, and the specific documentation requirements for chemotherapy and biologic therapies create a billing environment that demands dedicated specialty knowledge. Here is where general billing companies consistently fall short.

• Buy-and-bill drug reimbursement: When your practice purchases chemotherapy or biologic agents and administers them to patients, you bill payers for both the drug and the administration. Getting paid correctly requires accurate HCPCS drug codes, correct units based on the administered dose, and payer-specific pricing policies that vary by contract. Errors in any of these elements mean underpayment or denial on your highest-value claims.
• Prior authorization for every treatment cycle: Oncology has the most intensive prior authorization burden of any specialty. Most payers require authorization not just for initial treatment but for each subsequent cycle, for dose modifications, and when switching agents. A billing company without a proactive oncology prior authorization workflow will allow authorizations to lapse between cycles — causing claims denials on treatments that have already been administered.
• Medical necessity documentation: Payers scrutinize oncology claims for medical necessity more aggressively than almost any other service category. Chemotherapy claims must be supported by diagnosis, staging, and treatment protocol documentation that aligns with payer coverage policies. When documentation gaps exist, entire cycles get denied — and retroactive appeals are difficult because the documentation should have been in place before treatment began.
• Infusion billing complexity: Chemotherapy infusion billing involves multiple overlapping codes — the primary drug, secondary drugs, hydration, anti-nausea medications, and administration codes for each. Time-based infusion rules determine how administration codes are stacked across a single visit. Errors in infusion code sequencing or time documentation mean underpayment on every affected visit.
• Radiation oncology billing: Practices that provide both medical oncology and radiation oncology services face an additional layer of complexity — simulation codes, treatment planning, technical and professional components, and treatment delivery codes that each carry specific documentation and billing requirements.
• Clinical trial billing: Oncology practices participating in clinical trials face one of the most complex billing environments in medicine — determining which services are billable to insurance versus covered by the trial sponsor, applying correct modifiers, and maintaining the documentation required for trial-related claim audits.

Signs Your Oncology Practice Is Losing Revenue

Oncology revenue loss can be dramatic — large denied claims that are visible immediately — or it can be subtle — systematic underpayment on drug claims that only becomes apparent when you compare what was paid against what your contracts specify. Here are the warning signs.

• Your denial rate for chemotherapy or biologic drug claims exceeds 10% — or your billing company cannot tell you your oncology-specific denial rate
• You have had prior authorization lapses between treatment cycles that led to denied claims
• Your drug revenue seems low relative to the acquisition cost and volume of drugs you are administering
• You participate in clinical trials but you are unsure whether all billable services are being correctly identified and submitted
• Your billing company cannot show you a breakdown of drug reimbursement by HCPCS code against your contracted rates
• You write off denied oncology claims more frequently than you successfully appeal them
• Your billing company has never proactively audited your chemotherapy claims against payer fee schedules to identify systematic underpayments

What Specialist Oncology Billing Actually Looks Like

Specialist oncology billing is not just better general billing — it is a fundamentally different approach built around the specific financial mechanics of cancer care. Here is what it looks like when your billing partner genuinely understands oncology.

Oncology practices that switch to Medtransic's specialist oncology billing program typically see 15–25% more revenue within the first 90 days. In a specialty where drug claims routinely reach five figures, that difference is not a rounding error — it is the financial foundation your practice needs to continue delivering high-quality cancer care.

Choosing the Right Oncology Billing Partner

The stakes in oncology billing are higher than in almost any other specialty. Choosing the wrong billing partner does not just cost you percentage points of revenue — it exposes your practice to compliance risk, disrupts patient care when authorizations lapse, and can create cash flow problems severe enough to threaten your ability to maintain drug inventory. When evaluating billing companies, insist on specificity.

• Ask how they verify drug claim accuracy. A specialist will describe a specific process for reconciling HCPCS codes and units against the administered dose and your drug inventory. A general biller will tell you they bill what is submitted.
• Ask about their prior authorization workflow for oncology drugs. They should describe a proactive system that tracks authorization windows per patient per cycle, submits renewals in advance, and appeals initial denials with clinical evidence. Anything less will result in treatment-day authorization failures.
• Ask specifically how they handle buy-and-bill reimbursement. Can they show you how they audit drug payments against your contracted rates? Do they track Average Sales Price (ASP) updates for Medicare drug reimbursement? The specificity of their answer tells you immediately whether they have real oncology experience.
• Ask about clinical trial billing experience. If your practice participates in trials, this is non-negotiable. The billing rules are complex and the audit risk is significant — you need a partner who handles this correctly.
• Ask for oncology-specific client references. Practices with significant chemotherapy volume and biologic drug administration are the most relevant comparisons. Ask those references specifically about prior authorization management and drug reimbursement accuracy.

Also confirm that your billing partner manages prior authorizations in-house with oncology-specific expertise, handles credentialing and payer enrollment for oncologists and infusion nurses, and provides reporting that shows drug reimbursement by code, denial breakdown by reason, and AR aging by payer — not just aggregate revenue totals.

How Medtransic Helps Oncology Practices Protect Their Revenue

Medtransic's oncology billing program is built around the financial realities of cancer care — high drug costs, complex prior authorization requirements, and claims that cannot afford to be wrong. We handle every element of oncology revenue cycle management so your team can focus on patient outcomes instead of billing disputes.

• Oncology-dedicated billing team: Your practice works with billers who specialize in oncology — not a generalist team that handles your claims alongside primary care and orthopedics. They understand buy-and-bill reimbursement, chemotherapy infusion coding, and the prior authorization landscape for every major oncology drug class.
• Drug claim accuracy verification: Medtransic reconciles every drug claim against administered dose, verifies HCPCS codes and units before submission, and audits actual payments against your contracted rates — identifying underpayments proactively rather than discovering them in an annual contract review.
• Proactive prior authorization management: Our team tracks authorization windows for every patient on active treatment, submits renewals before authorizations lapse, and appeals initial denials with oncology-specific clinical documentation. Treatment-day authorization failures become a problem of the past.
• Infusion billing optimization: Medtransic captures every infusion visit at its full value — correct drug codes, time-based administration billing, hydration and supportive medication coding, and payer-specific infusion rules — ensuring your infusion suite generates every dollar it earns.
• MAGENTIC AI platform: Our proprietary MAGENTIC AI system applies oncology-specific claim validation, automated prior authorization tracking, and drug reimbursement auditing — reducing manual review burden while protecting your highest-value claims.
• Complete revenue cycle coverage: From eligibility and benefits verification before treatment begins to AR management for aged claims, Medtransic manages every stage of your oncology revenue cycle under one roof.
• Seamless transitions: Medtransic manages the complete transition from your previous billing company — in-flight drug claims, aged AR cleanup, prior authorization transfers, and payer enrollment updates — with no disruption to your treatment schedule or cash flow.

Whether you run a medical oncology practice, a radiation oncology center, a hematology-oncology group, or a multispecialty cancer center, Medtransic builds a billing program around your specific drug mix, treatment protocols, and payer contracts. Request your free audit today, or learn more about our full medical billing services and RCM automation platform.